- Home
- PLL vs PLX Comparison
PLL vs PLX Comparison
Compare PLL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- PLX
- Stock Information
- Founded
- PLL 2016
- PLX 1993
- Country
- PLL United States
- PLX Israel
- Employees
- PLL N/A
- PLX N/A
- Industry
- PLL Other Metals and Minerals
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLL Basic Materials
- PLX Health Care
- Exchange
- PLL Nasdaq
- PLX Nasdaq
- Market Cap
- PLL 195.1M
- PLX 160.2M
- IPO Year
- PLL 2017
- PLX 1998
- Fundamental
- Price
- PLL $9.08
- PLX $2.22
- Analyst Decision
- PLL Buy
- PLX
- Analyst Count
- PLL 9
- PLX 0
- Target Price
- PLL $22.04
- PLX N/A
- AVG Volume (30 Days)
- PLL 391.4K
- PLX 553.9K
- Earning Date
- PLL 02-20-2025
- PLX 03-13-2025
- Dividend Yield
- PLL N/A
- PLX N/A
- EPS Growth
- PLL N/A
- PLX N/A
- EPS
- PLL N/A
- PLX N/A
- Revenue
- PLL $46,981,000.00
- PLX $45,667,000.00
- Revenue This Year
- PLL $126.75
- PLX N/A
- Revenue Next Year
- PLL $35.26
- PLX $90.00
- P/E Ratio
- PLL N/A
- PLX N/A
- Revenue Growth
- PLL N/A
- PLX N/A
- 52 Week Low
- PLL $6.57
- PLX $0.82
- 52 Week High
- PLL $18.72
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- PLL 41.80
- PLX 74.10
- Support Level
- PLL $8.59
- PLX $2.11
- Resistance Level
- PLL $9.53
- PLX $2.36
- Average True Range (ATR)
- PLL 0.54
- PLX 0.12
- MACD
- PLL 0.10
- PLX 0.00
- Stochastic Oscillator
- PLL 30.23
- PLX 77.42
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.